Peter Stein
Peter Stein is a prominent figure in the pharmaceutical regulatory landscape, having served as the director of the Office of New Drugs at the FDA. He recently made headlines due to his resignation amid significant staff cuts within the agency, which have raised concerns about the future of drug evaluation and public health safety in the United States.
Global Media Ratings
Countries Mentioned
| Country | Mentions | Sentiment | Dominance | + Persistence | x Population | = Reach | x GDP (millions) | = Power |
|---|---|---|---|---|---|---|---|---|
| Guyana | 1 | 5.00 | 0.08% | +0% | 786,552 | 621 | $6,000 | 5$ |
| Slovakia | 1 | 4.00 | 0.04% | +0% | 5,459,642 | 2,072 | $110,000 | 42$ |
| Montenegro | 1 | 5.00 | 0.05% | +0% | 628,066 | 283 | $5,500 | 2$ |
| Totals | 3 | 6,874,260 | 2,976 | $121,500 | 49$ |
Interactive World Map
Each country's color is based on "Mentions" from the table above.
Recent Mentions
Guyana:
Peter Stein, the director of the Office of New Drugs at the FDA, resigned when faced with being fired.
5
Montenegro:
Peter Stein, director of the Office of New Drugs at the FDA, resigned yesterday in the face of termination.
5
Slovakia:
Peter Stein, the director of the Office of New Drugs at the FDA, resigned on Tuesday amid threats of dismissal.
4